Lazard Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $214M | Sell |
|
|||||
|
2025
Q1 | $258M | Buy |
|
|||||
|
2024
Q4 | $212M | Buy |
|
|||||
|
2024
Q3 | $3.71M | Sell |
|
|||||
|
2024
Q2 | $57.4M | Sell |
|
|||||
|
2024
Q1 | $51.8M | Buy |
|
|||||
|
2023
Q4 | $48.7M | Buy |
|
|||||
|
2023
Q3 | $41.4M | Sell |
|
|||||
|
2023
Q2 | $42.1M | Sell |
|
|||||
|
2023
Q1 | $40.2M | Sell |
|
|||||
|
2022
Q4 | $41.1M | Sell |
|
|||||
|
2022
Q3 | $181M | Sell |
|
|||||
|
2022
Q2 | $243M | Sell |
|
|||||
|
2022
Q1 | $234M | Sell |
|
|||||
|
2021
Q4 | $201M | Buy |
|
|||||
|
2021
Q3 | $30.1M | Buy |
|
|||||
|
2021
Q2 | $28.6M | Buy |
|
|||||
|
2021
Q1 | $24.9M | Sell |
|
|||||
|
2020
Q4 | $31.2M | Sell |
|
|||||
|
2020
Q3 | $56.1M | Buy |
|
|||||
|
2020
Q2 | $58.1M | Buy |
|
|||||
|
2020
Q1 | $13.9M | Buy |
|
|||||
|
2019
Q4 | $12.1M | Buy |
|
|||||
|
2019
Q3 | $9.2M | Sell |
|
|||||
|
2019
Q2 | $14.4M | Sell |
|
|||||
|
2019
Q1 | $15.9M | Buy |
|
|||||
|
2018
Q4 | $5.48M | Sell |
|
|||||
|
2018
Q3 | $7.51M | Buy |
|
|||||
|
2018
Q2 | $5.39M | Sell |
|
|||||
|
2018
Q1 | $26M | Sell |
|
|||||
|
2017
Q4 | $26.1M | Buy |
|
|||||
|
2017
Q3 | $26.4M | Sell |
|
|||||
|
2017
Q2 | $25.9M | Sell |
|
|||||
|
2017
Q1 | $49.9M | Sell |
|
|||||
|
2016
Q4 | $53.4M | Sell |
|
|||||
|
2016
Q3 | $104M | Sell |
|
|||||
|
2016
Q2 | $109M | Buy |
|
|||||
|
2016
Q1 | $78.1M | Buy |
|
|||||
|
2015
Q4 | $98.8M | Sell |
|
|||||
|
2015
Q3 | $130M | Sell |
|
|||||
|
2015
Q2 | $238M | Sell |
|
|||||
|
2015
Q1 | $246M | Sell |
|
|||||
|
2014
Q4 | $277M | Sell |
|
|||||
|
2014
Q3 | $284M | Sell |
|
|||||
|
2014
Q2 | $249M | Sell |
|
|||||
|
2014
Q1 | $195M | Sell |
|
|||||
|
2013
Q4 | $248M | Sell |
|
|||||
|
2013
Q3 | $257M | Sell |
|
|||||
|
2013
Q2 | $292M | Buy |
|